NEURODEVELOPMENTAL OUTCOMES AFTER ANTI-VEGF TREATMENT FOR RETINOPATHY OF PREMATURITY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Main Article Content

Nizma Permaisuari Julie Dewi Barliana

Abstract

Introduction: The objective of this study was to assess the neurodevelopmental outcomes in preterm infants who have undergone intravitreal anti-vascular endothelial growth factor (anti-VEGF), either as monotherapy or in combination with laser therapy, for treatment of retinopathy of prematurity (ROP). Secondary, efficacy of anti-VEGF was also evaluated.



Methods: Literature search was conducted using 7 online databases (CENTRAL, PubMed, ScienceDirect, SCOPUS, EBSCO, ProQuest, and JSTOR). Studies were selected based on the established inclusion and exclusion criteria. Primary outcomes were neurodevelopmental impairment (NDI), severe NDI (sNDI), neurodevelopmental scores, and cerebral palsy (CP) incidence. Secondary outcomes included impairment and severe impairment of each domain (motor, cognitive, and language) and retreatment of ROP.



Result: Seventeen studies were included. Random-effects model meta-analysis showed no differences were observed between anti-VEGF compared to control group in NDI (unadjusted odds ratio (uOR) 1.28; 95% confidence interval (CI) 0.85 to 1.94), sNDI (uOR 1.33; 95% CI 0.92 to 1.93), and CP outcomes . Meta-analysis showed insignificant result with lower overall scores, motor, cognitive, and language domains associated with anti-VEGF treatment. Secondary outcomes showed inferior cognitive impairment (OR 1.41; 95% CI: 1.03 to 1.92) and higher retreatment rate (OR 47.55; 95% CI: 12.35 to 183.09) in anti-VEGF group.



Conclusion: There were no differences in neurodevelopmental outcomes between anti-VEGF and control group. Despite not causing any adverse neurodevelopmental effect, clinicians should carefully weigh the benefits and risks of anti-VEGF injection for treating infants with ROP, since it has higher retreatment rate.

Keywords

Anti–vascular endothelial growth factor, neurodevelopmental, retinopathy of prematurity

Article Details

How to Cite
PERMAISUARI, Nizma; BARLIANA, Julie Dewi. NEURODEVELOPMENTAL OUTCOMES AFTER ANTI-VEGF TREATMENT FOR RETINOPATHY OF PREMATURITY: A SYSTEMATIC REVIEW AND META-ANALYSIS. International Journal of Retina, [S.l.], v. 6, n. 1, p. 30, mar. 2023. ISSN 2614-8536. Available at: <https://www.ijretina.com/index.php/ijretina/article/view/205>. Date accessed: 22 june 2024. doi: https://doi.org/10.35479/ijretina.2023.vol006.iss001.205.
Section
Article Review

References

1. Hered RW, Lee KA, Archer SM, Lueder GT, Braverman RS, O’Hara MA, et al. Disorders of the Retina and Vitreous. In: Rapuano CJ, Stout JT, McCannel CA, editors. 2020-2021 Basic and Clinical Science Course: Pediatric Ophthalmology and Strabismus. San Fransisco: American Academy of Ophthalmology; 2020. p. 325–35.
2. Kaushal M, Razak A, Patel W, Pullattayil AK, Kaushal A. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2021;41(6):1225–35.
3. Subramanian KS, Kern MD, Deegan WF. Retinopathy of Prematurity [Internet]. Medscape. 2021 [cited 2021 Dec 23]. Available from: https://emedicine.medscape.com/article/976220-overview#a4
4. Nicoară S. Indirect Diode Laser in the Treatment of Retinopathy of Prematurity. In: Ma Y, editor. Laser Technology and its Applications. Cluj-Napoca: IntechOpen; 2018. p. 107–22.
5. Quinn GE, Fielder AR. Retinopathy of prematurity. In: Lambert SR, Lyons CJ, editors. Taylor & Hoyt’s Pediatric Ophthalmology and Strabismus. 5th ed. Edinburgh: Elsevier; 2017. p. 443–55.
6. VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(5):619–33.
7. Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study. Ophthalmology. 2019;126(11):1567–77.
8. Enríquez AB, Avery RL, Baumal CR. Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity. Asia-Pacific J Ophthalmol. 2020;9(4):358–68.
9. Mutlu FM, Sarici SU. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol. 2013;6(2):228.
10. Hartnett ME. VEGF Antagonit Therapy for ROP. Clin Perinatol. 2014;41(4):925.
11. Kennedy KA, Mintz-Hittner HA. Medical and Developmental Outcomes of Bevacizumab versus Laser for Retinopathy of Prematurity. J Am Assoc Pediatr Ophthalmol Strabismus. 2018;22(1):1971–2.
12. Rodriguez SH, Peyton C, Lewis K, Andrews B, Greenwald MJ, Schreiber MD, et al. Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP. Ophthalmic Surg Lasers Imaging Retin. 2019;50(6):337–43.
13. Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of retinopathy of prematurity-use of anti-VEGF therapy. Asia-Pacific J Ophthalmol. 2018;7(1):56–62.
14. Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11(1):1–12.
15. Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153128.
16. Howick J, Chalmers I, Greenhalgh T, Carl H, Liberati A, Moschetti I, et al. OCEBM Levels of Evidence [Internet]. Oxford Centre for Evidence-Based Medicine. 2011 [cited 2022 Jan 12]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
17. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.
18. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.
19. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.
20. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):1–10.
21. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014 141. 2014;14(1):1–13.
22. JPT H, J T, J C, M C, T L, MJ P, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. JPT H, J T, J C, M C, T L, MJ P, et al., editors. Chichester: John Wiley & Sons; 2019.
23. Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, et al. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: Efficacy, anatomical outcomes and safety. Br J Ophthalmol. 2018;0:1–5.
24. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n71.
25. Natarajan G, Shankaran S, Nolen TL, Sridhar A, Kennedy KA, Hintz SR, et al. Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment. Pediatrics. 2019;144(2):e20183537.
26. Chang YS, Chen YT, Lai TT, Chou HC, Chen CY, Hsieh WS, et al. Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment. PLoS One. 2019;14(10):1–12.
27. Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up. Am J Perinatol. 2020;38(11):1158–66.
28. Eldweik L, Mantagos IS. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin Ophthalmol. 2016;31(1–2):163–8.
29. Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–61.
30. Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015 Apr 1;133(4):391–7.
31. Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, et al. Serum Vacular Endothelial Growth Factor after Bevacizumab or Ranibizumab Treatment for Retinopathy of Prematurity. Retina. 2017;37(4):694–701.
32. Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256(3):479–87.
33. Bagnard D, Vaillant C, Khuth ST, Dufay N, Lohrum M, Püschel AW, et al. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J Neurosci. 2001;21(10):3332–41.
34. Malik S, Vinukonda G, Vose LR, Diamond D, Bhimavarapu BBR, Hu F, et al. Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth. J Neurosci. 2013;33(2):411–23.
35. Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS One. 2020;15(3):1–7.
36. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):49.
37. Kono Y. Neurodevelopmental outcomes of very low birth weight infants in the Neonatal Research Network of Japan: importance of neonatal intensive care unit graduate follow-up. Clin Exp Pediatr. 2021;64(7):313–21.
38. Mercier CE, Dunn MS, Ferrelli KR, Howard DB, Soll RF. Neurodevelopmental Outcome of Extremely Low Birth Weight Infants from the Vermont Oxford Network: 1998–2003. Neonatology. 2010;97(4):329.
39. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ, et al. Neurodevelopmental and Functional Outcomes of Extremely Low Birth Weight Infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics. 2000;105(6):1216–26.
40. Glass TJA, Chau V, Gardiner J, Foong J, Vinall J, Zwicker JG, et al. Severe retinopathy of prematurity predicts delayed white matter maturation and poorer neurodevelopment. Arch Dis Child Fetal Neonatal Ed. 2017 Nov 1;102(6):F532–7.
41. Kumawat D, Sachan A, Shah P, Chawla R, Chandra P. Aggressive posterior retinopathy of prematurity: a review on current understanding. Eye (Lond). 2021 Apr 1;35(4):1140–58.
42. Murakami T, Sugiura Y, Okamoto F, Okamoto Y, Kato A, Hoshi S, et al. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefe’s Arch Clin Exp Ophthalmol. 2021;259(9):2849–55.
43. Altendahl M, Sim MS, Kokhanov A, Gundlach B, Tsui I, Chu A. Severe Retinopathy of Prematurity Is Not Independently Associated With Worse Neurodevelopmental Outcomes in Preterm Neonates. Front Pediatr. 2021 Jun 10;9.
44. Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018;18(1):1–10.
45. Xiang N, Zhao MJ, Li XY, Zheng HH, Li GG, Li B. Redundant Mechanisms for Vascular Growth Factors in Retinopathy of Prematurity in vitro. Ophthalmic Res. 2011 Jan;45(2):92–101.
46. Kong L, Dinh K, Schechet S, Coats D, Voigt R, Demny A, et al. Comparison of Ocular and Developmental Outcomes in Laser-and Bevacizumab-treated Infants with Retinopathy of Prematurity. Ophthalmol Res An Int J. 2015;3(1):13–22.
47. Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG, et al. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019;39(9):1300–8.
48. Chen TA, Schachar IH, Moshfeghi DM. Outcomes of Intravitreal Bevacizumab and Diode Laser Photocoagulation for Treatment-Warranted Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retin. 2018;49(2):126–31.
49. Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol. 2013;
50. Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017 Jun 1;135(6):654–6.
51. Araz-Ersan B, Kir N, Tuncer S, Aydinoglu-Candan O, Yildiz-Inec D, Akdogan B, et al. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. Curr Eye Res. 2015;40(6):585–91.
52. Johnson S, Moore T, Marlow N. Using the Bayley-II to assess neurodevelopmental delay: which cut-off should be used? Pediatr Res. 2014;75(5):670–4.
53. Tatsuta N, Suzuki K, Sugawara T, Nakai K, Hosokawa T, Satoh H. Comparison of Kyoto Scale of Psychological Development and Bayley Scales of Infant Development second edition among Japanese Infants. J Spec Educ Res. 2013;2(1):17–24.
54. Janzen D, Delaney KA, Shapiro EG. Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: A review of the literature. Mol Genet Metab. 2017;121(2):57–69.